Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Buy

Relative Strength Index

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

MorphoSys AG American Depositary Shares (MOR)

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/19/2018

Market Cap

2,856,343,112

Shares Outstanding

37,660,000

Weighted SO

150,378,152

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

IPSC --.--%

EWTX --.--%

CCCC --.--%

MLYS --.--%

CGEM --.--%

ACLX --.--%

VTYX --.--%

IMCR --.--%

PCVX --.--%

Beta

0.6620

Last Div

0.0000

Range

4.185-19.5

Chg

0.4500

Avg Vol

54015

Mkt Cap

2856343112

Exch

NASDAQ

Country

DE

Phone

49 89 89927 0

DCF Diff

0.0077

DCF

4.9323

Div Yield

0.0000

P/S

12.7349

EV Multiple

-8.3063

P/FV

-9.8963

Div Yield %

0.0000

P/E

-5.6262

PEG

-0.2360

Payout

0.0000

Current Ratio

1.3837

Quick Ratio

1.3837

Cash Ratio

0.2691

DSO

55.2763

DIO

0.0000

Op Cycle

55.2763

DPO

642.6878

CCC

-587.4115

Gross Margin

0.7975

Op Margin

-2.1973

Pretax Margin

-2.2396

Net Margin

-2.2608

Eff Tax Rate

-0.0602

ROA

-0.2513

ROE

7.4262

ROCE

-0.3329

NI/EBT

1.0095

EBT/EBIT

1.0192

EBIT/Rev

-2.1973

Debt Ratio

0.1379

D/E

-0.9649

LT Debt/Cap

-16.4526

Total Debt/Cap

-27.4755

Int Coverage

-4.1841

CF/Debt

-1.1107

Equity Multi

-6.9995

Rec Turnover

6.6032

Pay Turnover

0.5679

Inv Turnover

999999.9999

FA Turnover

18.5899

Asset Turnover

0.1112

OCF/Share

-1.8636

FCF/Share

-1.8802

Cash/Share

4.1919

OCF/Sales

-1.3774

FCF/OCF

1.0089

CF Coverage

-1.1107

ST Coverage

-48.3173

CapEx Coverage

-112.3155

Div&CapEx Cov

-112.3155

P/BV

-9.8963

P/B

-9.8963

P/S

12.7349

P/E

-5.6262

P/FCF

-9.1637

P/OCF

-9.2344

P/CF

-9.2344

PEG

-0.2360

P/S

12.7349

EV Multiple

-8.3063

P/FV

-9.8963

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 28, 20:00 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses The Motley Fool May 28, 22:37 What's on Jamie Dimon's Mind? The Motley Fool Jan 03, 06:15 This Growth Stock Soared 391% in 2023. It Could Fall 48% in 2024, According to Wall Street. Benzinga Dec 15, 13:00 Analyst Expectations for MorphoSys's Future The Motley Fool Dec 11, 05:12 Wall Street Says the S&P 500 Is Headed Higher in 2024: 2 No-Brainer Growth Stocks to Buy Now With $200 and Hold Long Term Seeking Alpha Dec 05, 00:10 The Fourth Quarter Started Slow, But It May Finish Strong Seeking Alpha Nov 10, 00:18 U.S. Could Soon See 2% Inflation Seeking Alpha Nov 10, 00:18 U.S. Could Soon See 2% Inflation

Revenue Product Segmentation